Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
1998

Effects of LY231514 on Cancer Cells

publication Evidence: moderate

Author Information

Author(s): VJ Chen, JR Bewley, SL Andis, RM Schultz, PW Iversen, C Shih, LG Mendelsohn, DE Seitz, JL Tonkinson

Primary Institution: Lilly Research Laboratories

Hypothesis

LY231514 could be a multitargeted antifolate capable of inhibiting multiple folate-dependent enzymes.

Conclusion

LY231514 is distinct from other antifolates and primarily affects the thymidylate cycle in CCRF-CEM cells.

Supporting Evidence

  • LY231514 had minimal effects on folate pools but caused rapid depletion of certain nucleotides.
  • Raltitrexed and LY231514 induced different rates of dATP accumulation.
  • LY231514's effects were distinct from those of methotrexate and LY309887.

Takeaway

LY231514 is a new cancer drug that works differently than others by targeting specific processes in cancer cells.

Methodology

The study compared the effects of LY231514, methotrexate, raltitrexed, and LY309887 on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

Limitations

The study was conducted in vitro, and results may not fully translate to in vivo conditions.

Statistical Information

P-Value

0.011

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication